Anti-infliximab antibodies: How to compare old and new data?
Sign Up to like & getrecommendations! Published in 2019 at "Journal of pharmaceutical and biomedical analysis"
DOI: 10.1016/j.jpba.2019.112842
Abstract: BACKGROUND Anti-drug-antibodies (ADA) against infliximab are frequently measured in patients receiving infliximab treatment with loss of response and undetectable infliximab concentrations. Different ADA bridging assays (1st generation, 2nd generation and ready-to-use kit) have been developed… read more here.
Keywords: 2nd generation; ready use; generation; 1st generation ... See more keywords
P966 The intra-patient variability of adalimumab clearance during an intensive sampling study of Crohn’s disease patients receiving maintenance therapy
Sign Up to like & getrecommendations! Published in 2024 at "Journal of Crohn's and Colitis"
DOI: 10.1093/ecco-jcc/jjad212.1096
Abstract: Lower adalimumab (ADA) clearance (CL) is associated with improved outcomes in Crohn’s disease (CD) and may be a superior pharmacokinetic (PK) measure than ADA concentrations. We compared intra-patient variability in ADA CL and concentrations within… read more here.
Keywords: patient variability; intra patient; day; ada concentrations ... See more keywords
Relationship between clinical remission of perianal fistulas in Crohn’s disease and serum adalimumab concentrations: A multi-center cross-sectional study
Sign Up to like & getrecommendations! Published in 2022 at "World Journal of Gastroenterology"
DOI: 10.3748/wjg.v28.i9.961
Abstract: BACKGROUND Crohn’s disease (CD) is complicated by perianal fistulas in approximately 20% of patients. Achieving permanent fistula closure remains a challenge for physicians. An association between serum anti-tumor necrosis factor-α concentrations and clinical outcomes in… read more here.
Keywords: clinical remission; ada concentrations; perianal fistulas; remission ... See more keywords